DR-30206

N/A

Report date: 2026/02/27 20:01:47

Base Information

Drug NameDR-30206
Drug Alias NameDR-30206
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibody
Mechanisms of ActionProgrammed death-ligand 1 blockersTransforming growth factor beta inhibitorsVascular endothelial growth factor inhibitors
TargetsProgrammed death-ligand 1Transforming growth factor betaVascular endothelial growth factor
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungGastrointestinal Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesZhejiang Doer Biologics Corp
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesZhejiang Doer Biologics Corp
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungGastrointestinal Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A